EE05378B1 - LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks - Google Patents

LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks

Info

Publication number: EE05378B1
Authority: EE; Estonia
Prior art keywords: molecule; soluble; preparation; pharmaceutical composition; pharmaceutical
Prior art date: 2000-07-03

Application number

EEP200300004A

Other languages

English (en)

Estonian (et)

Inventor

Robert�Cohen

Suzette�Carr

David�Hagerty

Robert�J.�Peach

Jean-Claude�Becker

Original Assignee

Bristol-Myers�Squibb�Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-03

Filing date

2001-07-02

Publication date

2011-02-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22804919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05378(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-07-02 Application filed by Bristol-Myers�Squibb�Company filed Critical Bristol-Myers�Squibb�Company

2004-10-15 Publication of EE200300004A publication Critical patent/EE200300004A/xx

2011-02-15 Publication of EE05378B1 publication Critical patent/EE05378B1/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Zoology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Oncology (AREA)
Transplantation (AREA)

EEP200300004A 2000-07-03 2001-07-02 LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks EE05378B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21591300P	2000-07-03	2000-07-03
PCT/US2001/021204 WO2002002638A2 (en)	2000-07-03	2001-07-02	Methods for treating rheumatic diseases using a soluble ctla4 molecule

Publications (2)

Publication Number	Publication Date
EE200300004A EE200300004A (et)	2004-10-15
EE05378B1 true EE05378B1 (et)	2011-02-15

Family

ID=22804919

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300004A EE05378B1 (et)	2000-07-03	2001-07-02	LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks

Country Status (38)

Country	Link
US (1)	US7455835B2 (de)
EP (4)	EP1935427B1 (de)
JP (1)	JP2004517806A (de)
KR (3)	KR20030017606A (de)
CN (1)	CN1318086C (de)
AR (2)	AR035037A1 (de)
AT (1)	ATE401909T1 (de)
AU (2)	AU2001273174B2 (de)
BG (2)	BG66024B1 (de)
BR (1)	BR0112104A (de)
CA (2)	CA2630062C (de)
CY (3)	CY1109786T1 (de)
CZ (1)	CZ303959B6 (de)
DE (1)	DE60135029D1 (de)
DK (2)	DK1935427T3 (de)
EE (1)	EE05378B1 (de)
ES (2)	ES2667203T3 (de)
HR (1)	HRP20030071B1 (de)
HU (3)	HU226847B1 (de)
IL (2)	IL153593A0 (de)
IS (1)	IS2834B (de)
LT (2)	LT1935427T (de)
LV (1)	LV12993B (de)
MX (1)	MXPA02012603A (de)
MY (1)	MY137552A (de)
NO (3)	NO20026264L (de)
PE (1)	PE20020772A1 (de)
PL (2)	PL207534B1 (de)
PT (2)	PT1372696E (de)
RS (1)	RS50811B (de)
RU (1)	RU2287340C2 (de)
SI (3)	SI1935427T1 (de)
SK (1)	SK287940B6 (de)
TR (1)	TR201807700T4 (de)
TW (2)	TWI322153B (de)
UY (1)	UY26815A1 (de)
WO (1)	WO2002002638A2 (de)
ZA (1)	ZA200210058B (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6887471B1 (en) *	1991-06-27	2005-05-03	Bristol-Myers Squibb Company	Method to inhibit T cell interactions with soluble B7
US5637481A (en)	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ATE219376T1 (de) *	1996-03-20	2002-07-15	Bristol Myers Squibb Co	Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
ZA98533B (en) *	1997-01-31	1999-07-22	Bristol Myers Squibb Co	Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) *	1997-01-31	2003-11-27	Bristol-Myers Squibb Company	Soluble CTLA4 mutant molecules and uses thereof
TWI314933B (en) *	2000-05-26	2009-09-21	Bristol Myers Squibb Compan	Soluble ctla4 mutant molecules and uses thereof
US7094874B2 (en)	2000-05-26	2006-08-22	Bristol-Myers Squibb Co.	Soluble CTLA4 mutant molecules
MXPA02012157A (es) *	2000-06-09	2003-06-06	Bristol Myers Squibb Co	Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
US20040022787A1 (en)	2000-07-03	2004-02-05	Robert Cohen	Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2630062C (en) *	2000-07-03	2014-10-14	Bristol-Myers Squibb Company	Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule
MXPA03006699A (es) *	2001-01-26	2004-05-31	Univ Emory	Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias.
ATE390931T1 (de) *	2001-05-23	2008-04-15	Bristol Myers Squibb Co	Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
CA2482042A1 (en) *	2002-04-19	2003-10-30	Bristol-Myers Squibb Company	Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
EP1575998A4 (de) *	2002-12-23	2007-07-25	Bristol Myers Squibb Co	Verfahren zur kultivierung vonsäugetierzellen zur proteinproduktion
TWI328614B (en) *	2002-12-23	2010-08-11	Bristol Myers Squibb Co	Product quality enhancement in mammalian cell culture processes for protein production
WO2004060911A2 (en)	2002-12-30	2004-07-22	Amgen Inc.	Combination therapy with co-stimulatory factors
NZ545314A (en) *	2003-08-04	2009-03-31	Bristol Myers Squibb Co	Methods for treating cardiovascular disease using a soluble CTLA4 molecule
EP1684791A4 (de)	2003-10-27	2009-07-01	Amgen Inc	Zusammensetzungen und verfahren zur modulierung einer immunantwort auf ein immunogenes therapeutisches mittel
US7815765B2 (en) *	2004-04-01	2010-10-19	Swei Mu Wang	Method for forming laminated synthetic leather
PT2253644E (pt) *	2005-12-20	2014-01-23	Bristol Myers Squibb Co	Composições e métodos para a produção de uma composição
AR058568A1 (es)	2005-12-20	2008-02-13	Bristol Myers Squibb Co	Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
TW200738261A (en)	2005-12-20	2007-10-16	Bristol Myers Squibb Co	Stable protein formulations
US9309316B2 (en)	2005-12-20	2016-04-12	Bristol-Myers Squibb Company	Stable subcutaneous protein formulations and uses thereof
US7528111B2 (en)	2006-05-12	2009-05-05	Bristol-Myers Squibb Company	Method of vaccinating subjects receiving immune modulating therapy
GB0620934D0 (en)	2006-10-20	2006-11-29	Cambridge Antibody Tech	Protein variants
AU2014250683B2 (en) *	2007-11-01	2015-11-26	Astellas Pharma Inc.	Immunosuppressive polypeptides and nucleic acids
AU2012202324B2 (en) *	2007-11-01	2014-08-28	Astellas Pharma Inc.	Immunosuppressive polypeptides and nucleic acids
CA2703263C (en) *	2007-11-01	2014-03-18	Perseid Therapeutics Llc	Immunosuppressive polypeptides and nucleic acids
US8986253B2 (en)	2008-01-25	2015-03-24	Tandem Diabetes Care, Inc.	Two chamber pumps and related methods
US7915222B2 (en)	2008-05-05	2011-03-29	Bristol-Myers Squibb Company	Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
US8408421B2 (en)	2008-09-16	2013-04-02	Tandem Diabetes Care, Inc.	Flow regulating stopcocks and related methods
EP2334234A4 (de)	2008-09-19	2013-03-20	Tandem Diabetes Care Inc	Vorrichtung zur messung der konzentration eines gelösten stoffs und entsprechende verfahren
WO2010042433A1 (en)	2008-10-06	2010-04-15	Bristol-Myers Squibb Company	Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
WO2010049935A1 (en) *	2008-10-30	2010-05-06	Yeda Research And Development Co. Ltd.	Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US8758323B2 (en)	2009-07-30	2014-06-24	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN102030828B (zh) *	2009-09-25	2014-10-29	上海抗体药物国家工程研究中心有限公司	一种高亲和力的CTLA4-Ig融合蛋白突变体
EP3053932B1 (de)	2010-02-19	2020-07-22	Xencor, Inc.	Neuartige ctla4-ig-immunadhäsine
WO2011113019A2 (en) *	2010-03-12	2011-09-15	Abbott Biotherapeutics Corp.	Ctla4 proteins and their uses
WO2011146395A2 (en)	2010-05-17	2011-11-24	The Board Of Trustees Of The Leland Stanford Junior University	Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
ES2589678T3 (es)	2010-09-08	2016-11-15	Yeda Research And Development Co. Ltd.	Uso de linfocitos T de memoria central anti-terceros para el tratamiento anti-leucemia/linfoma
EP2614083A2 (de)	2010-09-08	2013-07-17	Yeda Research and Development Co. Ltd	Immunsuppresive wirkstoffkombination für stabiles und langfristiges anwachsen
WO2013010537A1 (en) *	2011-07-20	2013-01-24	Aarhus Universitet	Method of treating morphea
SG11201400513PA (en)	2011-09-08	2014-06-27	Yeda Res & Dev	Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US9180242B2 (en)	2012-05-17	2015-11-10	Tandem Diabetes Care, Inc.	Methods and devices for multiple fluid transfer
US8735359B2 (en)	2012-05-24	2014-05-27	Orban Biotech Llc	Combinations of modalities for the treatment of diabetes
US9555186B2 (en)	2012-06-05	2017-01-31	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
AU2013284460A1 (en)	2012-06-27	2015-01-29	Dmnomore	CTLA4 fusion proteins for the treatment of diabetes
US9173998B2 (en)	2013-03-14	2015-11-03	Tandem Diabetes Care, Inc.	System and method for detecting occlusions in an infusion pump
WO2014151230A2 (en)	2013-03-15	2014-09-25	Bristol-Myers Squibb Company	Method of treating granulomatosis with polyangiitis
CN104740608A (zh) *	2013-12-30	2015-07-01	上海中信国健药业股份有限公司	可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
GB2523399B (en)	2014-02-25	2019-03-13	Orban Tihamer	A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
WO2015164595A1 (en) *	2014-04-25	2015-10-29	Bristol-Myers Squibb Company	Use of ctla4 compound for achieving drug-free remission in subjects with early ra
SMT202100467T1 (it)	2015-04-17	2021-09-14	Alpine Immune Sciences Inc	Proteine immunomodulatorie con affinità regolabili
AU2016291825B2 (en)	2015-07-16	2022-08-11	Yeda Research And Development Co. Ltd.	Genetically modified anti-third party central memory T cells and use of same in immunotherapy
EP3192805A1 (de)	2016-01-15	2017-07-19	Humanitas Mirasole S.p.A.	Inhibitoren von t-zellaktivierung oder stimulation und verwendungen davon
AU2017248830B2 (en)	2016-04-15	2023-03-09	Alpine Immune Sciences, Inc.	CD80 variant immunomodulatory proteins and uses thereof
EP3491013A1 (de)	2016-07-28	2019-06-05	Alpine Immune Sciences, Inc.	Cd155-variante immunmodulatorische proteine und verwendungen davon
ES3064681T3 (en)	2017-01-18	2026-04-28	Yeda Res & Dev	Genetically modified veto cells and use of same in immunotherapy
US10751368B2 (en)	2017-01-18	2020-08-25	Yeda Research And Development Co. Ltd.	Methods of transplantation and disease treatment
EP3694870A1 (de)	2017-10-10	2020-08-19	Alpine Immune Sciences, Inc.	Ctla-4-variante immunmodulatorische proteine und verwendungen davon
JP7282760B2 (ja)	2017-10-18	2023-05-29	アルパインイミューンサイエンシズインコーポレイテッド	バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
SG11202006148UA (en)	2018-01-03	2020-07-29	Alpine Immune Sciences Inc	Multi-domain immunomodulatory proteins and methods of use thereof
EP3765053A2 (de)	2018-03-16	2021-01-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antigene peptide aus urocortin 3 und verwendungen davon zur diagnose und behandlung von typ-1-diabetes
US20210023209A1 (en)	2018-03-16	2021-01-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019175380A2 (en)	2018-03-16	2019-09-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
CN113508129B (zh)	2019-01-15	2025-02-18	法国国家健康和医学研究院	突变的白介素-34(il-34)多肽及其在治疗中的用途
US12202882B2 (en)	2020-05-08	2025-01-21	Alpine Immune Sciences, Inc.	APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
JP2025016812A (ja) *	2021-12-16	2025-02-05	レグセル株式会社	免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US644792A (en) *	1899-09-14	1900-03-06	Stanhope Boal	Heater.
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DE3424893A1 (de)	1984-07-06	1986-02-06	Agfa-Gevaert Ag, 5090 Leverkusen	Photographisches silberhalogenidaufzeichnungsmaterial
US6905680B2 (en) *	1988-11-23	2005-06-14	Genetics Institute, Inc.	Methods of treating HIV infected subjects
US6685941B1 (en) *	1988-11-23	2004-02-03	The Regents Of The University Of Michigan	Methods of treating autoimmune disease via CTLA-4Ig
CA2003455C (en) *	1988-11-23	2000-02-22	Craig B. Thompson	Immunotherapy involving cd28 stimulation
US5858358A (en) *	1992-04-07	1999-01-12	The United States Of America As Represented By The Secretary Of The Navy	Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) *	1994-06-03	2002-03-05	Genetics Institute, Inc.	Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US7070776B1 (en) *	1990-03-26	2006-07-04	Bristol-Myers Squibb Company	Methods for blocking binding of CD28 receptor to B7
US6641809B1 (en) *	1990-03-26	2003-11-04	Bristol-Myers Squibb Company	Method of regulating cellular processes mediated by B7 and CD28
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
US6277969B1 (en) *	1991-03-18	2001-08-21	New York University	Anti-TNF antibodies and peptides of human tumor necrosis factor
US5844095A (en)	1991-06-27	1998-12-01	Bristol-Myers Squibb Company	CTLA4 Ig fusion proteins
US5637481A (en) *	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6090914A (en) *	1991-06-27	2000-07-18	Bristol-Myers Squibb Company	CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5851795A (en)	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
US5770197A (en)	1991-06-27	1998-06-23	Bristol-Myers Squibb Company	Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
DE69226871T3 (de)	1991-06-27	2009-09-24	Bristol-Myers Squibb Co.	CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5624823A (en) *	1991-11-22	1997-04-29	The General Hospital Corporation	DNA encoding procine interleukin-10
US5958403A (en) *	1992-02-28	1999-09-28	Beth Israel Hospital Association	Methods and compounds for prevention of graft rejection
CA2133075A1 (en)	1992-04-07	1993-10-14	Craig B. Thompson	CD28 Pathway Immunoregulation
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
US5747034A (en) *	1992-07-09	1998-05-05	Chiron Corporation	Methods and materials for the induction of T cell anergy
US5773253A (en)	1993-01-22	1998-06-30	Bristol-Myers Squibb Company	MYPPPY variants of CTL A4 and uses thereof
CA2164226C (en)	1993-06-04	2011-02-08	Carl H. June	Methods for selectively stimulating proliferation of t cells
AU7107794A (en)	1993-06-10	1995-01-03	Regents Of The University Of Michigan, The	Cd28 pathway immunosuppression
CN1127351C (zh)	1993-09-02	2003-11-12	达特茅斯学院理事	诱导抗原特异性ｔ细胞耐受的方法
CZ282294B6 (cs) *	1993-12-01	1997-06-11	Sankyo Company Limited	Inhibitor tvorby zánětlivého cytokinu obsahující polyprenylové deriváty, činidlo pro profylaxi a terapii zánětlivých střevních onemocnění a použití polyprenylových derivátů
US5683693A (en)	1994-04-25	1997-11-04	Trustees Of Dartmouth College	Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US6719972B1 (en)	1994-06-03	2004-04-13	Repligen Corporation	Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
WO1995033823A1 (en)	1994-06-03	1995-12-14	The United States Of America, Represented By The Secretary Of The Navy	Methods for selectively stimulating proliferation of t cells
CA2191733A1 (en)	1994-06-07	1995-12-21	Daniel A. Vallera	Methods for inhibiting antigen specific t cell responses
US5634055A (en) *	1994-09-27	1997-05-27	Bidplus, Inc.	Method for selecting assignments
AU4158396A (en)	1994-11-10	1996-06-06	Dana-Farber Cancer Institute	Methods for inhibiting graft versus host disease in bone marrow transplantation
US5876950A (en)	1995-01-26	1999-03-02	Bristol-Myers Squibb Company	Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5824655A (en)	1995-02-15	1998-10-20	The University Of Utah	Anti-transforming growth factor-β gene therapy
US5993800A (en) *	1995-06-05	1999-11-30	Bristol-Myers Squibb Company	Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US6113898A (en)	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6750334B1 (en)	1996-02-02	2004-06-15	Repligen Corporation	CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
ATE219376T1 (de) *	1996-03-20	2002-07-15	Bristol Myers Squibb Co	Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
JPH1067653A (ja) *	1996-06-17	1998-03-10	Eisai Co Ltd	関節疾患治療剤
US6495579B1 (en) *	1996-12-02	2002-12-17	Angiotech Pharmaceuticals, Inc.	Method for treating multiple sclerosis
KR19980066046A (ko)	1997-01-18	1998-10-15	정용훈	고역가의 CTLA4-Ig 융합단백질
US20030219863A1 (en) *	1997-01-31	2003-11-27	Bristol-Myers Squibb Company	Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) *	1997-01-31	1999-07-22	Bristol Myers Squibb Co	Soluble CTLA4 mutant molecules and uses thereof.
EP1009432A4 (de)	1997-06-11	2004-07-07	Us Navy	Zusammensetzungen und methoden zur hemmung von transplantatabstossung und anderen gegen die annahme gerichteten von t-lymphozyten vermittelten immunantworten
EP0947524A1 (de) *	1998-03-30	1999-10-06	Upither B.V.	Neue Peptide zur Behandlung von Autoimmunkrankheiten
JP2002510655A (ja) *	1998-04-03	2002-04-09	オシリスセラピューティクス，インコーポレイテッド	免疫抑制剤としての間葉幹細胞によるｔ細胞応答を阻害する方法とその利用
JP2002516867A (ja) *	1998-06-05	2002-06-11	スーパージェンインコーポレイテッド	リウマチ様関節炎を治療するためのメトトレキセート及びペントスタチンを含む組成物
JP2000086519A (ja) *	1998-09-17	2000-03-28	Mitsui Chemicals Inc	抗リウマチ薬効果増強剤
IL126681A0 (en)	1998-10-21	1999-08-17	Opperbas Holding Bv	Treatment of trauma-related conditions
US6040292A (en) *	1999-06-04	2000-03-21	Celtrix Pharmaceuticals, Inc.	Methods for treating diabetes
AU2001233027A1 (en)	2000-01-27	2001-08-07	Genetics Institute, Llc	Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
WO2001090122A2 (en)	2000-05-23	2001-11-29	Genaissance Pharmaceuticals, Inc.	Haplotypes of the ctla4 gene
TWI314933B (en) *	2000-05-26	2009-09-21	Bristol Myers Squibb Compan	Soluble ctla4 mutant molecules and uses thereof
US7094874B2 (en) *	2000-05-26	2006-08-22	Bristol-Myers Squibb Co.	Soluble CTLA4 mutant molecules
MXPA02012157A (es) *	2000-06-09	2003-06-06	Bristol Myers Squibb Co	Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
US20040022787A1 (en) *	2000-07-03	2004-02-05	Robert Cohen	Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2630062C (en) *	2000-07-03	2014-10-14	Bristol-Myers Squibb Company	Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule
MXPA03006699A (es) *	2001-01-26	2004-05-31	Univ Emory	Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias.
ATE390931T1 (de) *	2001-05-23	2008-04-15	Bristol Myers Squibb Co	Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen

2001
- 2001-07-02 CA CA2630062A patent/CA2630062C/en not_active Expired - Lifetime
- 2001-07-02 HU HU0301727A patent/HU226847B1/hu active Protection Beyond IP Right Term
- 2001-07-02 ES ES08001340.2T patent/ES2667203T3/es not_active Expired - Lifetime
- 2001-07-02 EE EEP200300004A patent/EE05378B1/xx active Protection Beyond IP Right Term
- 2001-07-02 CZ CZ20024261A patent/CZ303959B6/cs not_active IP Right Cessation
- 2001-07-02 MX MXPA02012603A patent/MXPA02012603A/es active IP Right Grant
- 2001-07-02 MY MYPI20013159A patent/MY137552A/en unknown
- 2001-07-02 TW TW097137769A patent/TWI322153B/zh not_active IP Right Cessation
- 2001-07-02 KR KR10-2003-7000018A patent/KR20030017606A/ko not_active Ceased
- 2001-07-02 TW TW090116137A patent/TWI311564B/zh not_active IP Right Cessation
- 2001-07-02 DK DK08001340.2T patent/DK1935427T3/en active
- 2001-07-02 PL PL365942A patent/PL207534B1/pl unknown
- 2001-07-02 RU RU2003103098/14A patent/RU2287340C2/ru active
- 2001-07-02 KR KR1020087005505A patent/KR100864120B1/ko not_active Expired - Lifetime
- 2001-07-02 JP JP2002507889A patent/JP2004517806A/ja active Pending
- 2001-07-02 DE DE60135029T patent/DE60135029D1/de not_active Expired - Lifetime
- 2001-07-02 AR ARP010103156A patent/AR035037A1/es active IP Right Grant
- 2001-07-02 CA CA002413190A patent/CA2413190C/en not_active Expired - Lifetime
- 2001-07-02 LT LTEP08001340.2T patent/LT1935427T/lt unknown
- 2001-07-02 HU HU0900660A patent/HU227669B1/hu unknown
- 2001-07-02 AU AU2001273174A patent/AU2001273174B2/en not_active Expired
- 2001-07-02 ES ES01952420T patent/ES2310557T3/es not_active Expired - Lifetime
- 2001-07-02 AU AU7317401A patent/AU7317401A/xx active Pending
- 2001-07-02 EP EP08001340.2A patent/EP1935427B1/de not_active Expired - Lifetime
- 2001-07-02 WO PCT/US2001/021204 patent/WO2002002638A2/en not_active Ceased
- 2001-07-02 CN CNB018122299A patent/CN1318086C/zh not_active Expired - Lifetime
- 2001-07-02 PT PT01952420T patent/PT1372696E/pt unknown
- 2001-07-02 KR KR1020087019039A patent/KR100895552B1/ko not_active Expired - Lifetime
- 2001-07-02 SK SK1774-2002A patent/SK287940B6/sk not_active IP Right Cessation
- 2001-07-02 IL IL15359301A patent/IL153593A0/xx unknown
- 2001-07-02 SI SI200131067T patent/SI1935427T1/en unknown
- 2001-07-02 DK DK01952420T patent/DK1372696T3/da active
- 2001-07-02 EP EP01952420A patent/EP1372696B1/de not_active Expired - Lifetime
- 2001-07-02 UY UY26815A patent/UY26815A1/es not_active Application Discontinuation
- 2001-07-02 PL PL389002A patent/PL212205B1/pl unknown
- 2001-07-02 US US09/898,195 patent/US7455835B2/en not_active Expired - Lifetime
- 2001-07-02 EP EP18158752.8A patent/EP3384924A1/de not_active Withdrawn
- 2001-07-02 EP EP10184596.4A patent/EP2281568A3/de not_active Withdrawn
- 2001-07-02 BR BR0112104-9A patent/BR0112104A/pt not_active Application Discontinuation
- 2001-07-02 HR HRP20030071AA patent/HRP20030071B1/hr not_active IP Right Cessation
- 2001-07-02 PT PT80013402T patent/PT1935427T/pt unknown
- 2001-07-02 RS YUP-1011/02A patent/RS50811B/sr unknown
- 2001-07-02 SI SI200120046A patent/SI21078A/sl not_active IP Right Cessation
- 2001-07-02 TR TR2018/07700T patent/TR201807700T4/tr unknown
- 2001-07-02 AT AT01952420T patent/ATE401909T1/de active
- 2001-07-02 SI SI200130864T patent/SI1372696T1/sl unknown
- 2001-11-14 PE PE2001001131A patent/PE20020772A1/es not_active Application Discontinuation
2002
- 2002-12-06 BG BG107362A patent/BG66024B1/bg unknown
- 2002-12-11 ZA ZA2002/10058A patent/ZA200210058B/en unknown
- 2002-12-23 IL IL153593A patent/IL153593A/en active IP Right Grant
- 2002-12-27 NO NO20026264A patent/NO20026264L/no not_active Application Discontinuation
2003
- 2003-01-02 IS IS6667A patent/IS2834B/is unknown
- 2003-01-07 LT LT2003002A patent/LT5063B/lt not_active IP Right Cessation
- 2003-02-03 LV LVP-03-08A patent/LV12993B/en unknown
2008
- 2008-05-09 AR ARP080101975A patent/AR066511A2/es unknown
- 2008-10-21 CY CY20081101167T patent/CY1109786T1/el unknown
- 2008-11-05 CY CY2008017C patent/CY2008017I2/el unknown
2010
- 2010-03-05 BG BG110611A patent/BG66454B1/bg unknown
- 2010-04-22 NO NO20100580A patent/NO20100580L/no not_active Application Discontinuation
- 2010-04-22 NO NO20100579A patent/NO20100579L/no unknown
- 2010-04-27 HU HUS1000008C patent/HUS1000008I1/hu unknown
2018
- 2018-05-23 CY CY20181100546T patent/CY1120577T1/el unknown

Also Published As

Publication number	Publication date
DE60135029D1 (de)	2008-09-04
TWI311564B (en)	2009-07-01
AU7317401A (en)	2002-01-14
ZA200210058B (en)	2005-02-23
EP2281568A3 (de)	2013-04-24
LV12993B (en)	2003-10-20
DK1372696T3 (da)	2008-11-03
ES2310557T3 (es)	2009-01-16
CY1120577T1 (el)	2019-07-10
PL365942A1 (en)	2005-01-24
NO20100580L (no)	2003-02-19
KR20080025216A (ko)	2008-03-19
IL153593A (en)	2009-09-01
WO2002002638A3 (en)	2003-10-30
AU2001273174B2 (en)	2006-05-18
LT1935427T (lt)	2018-05-10
PE20020772A1 (es)	2002-09-06
HK1058486A1 (en)	2004-05-21
CY1109786T1 (el)	2011-04-06
HU227669B1 (en)	2011-11-28
SK287940B6 (sk)	2012-05-03
TW200902546A (en)	2009-01-16
DK1935427T3 (en)	2018-06-06
CA2413190C (en)	2009-04-07
BG107362A (bg)	2003-09-30
HUP0301727A3 (en)	2008-08-28
CZ20024261A3 (cs)	2004-08-18
KR20080075564A (ko)	2008-08-18
SI1935427T1 (en)	2018-05-31
WO2002002638A2 (en)	2002-01-10
RS50811B (sr)	2010-08-31
MY137552A (en)	2009-02-27
HRP20030071B1 (hr)	2014-01-03
CN1318086C (zh)	2007-05-30
NO20100579L (no)	2003-02-19
BG110611A (bg)	2010-05-31
US20030083246A1 (en)	2003-05-01
EP2281568A2 (de)	2011-02-09
EP1372696A2 (de)	2004-01-02
SI21078A (sl)	2003-06-30
SK17742002A3 (sk)	2004-11-03
CA2630062A1 (en)	2002-01-10
SI1372696T1 (sl)	2008-12-31
BR0112104A (pt)	2004-07-20
HUP0301727A2 (hu)	2003-09-29
US7455835B2 (en)	2008-11-25
CY2008017I1 (el)	2009-11-04
CY2008017I2 (el)	2016-08-31
EP1935427B1 (de)	2018-03-07
TWI322153B (en)	2010-03-21
EP1935427A2 (de)	2008-06-25
CN1477968A (zh)	2004-02-25
HUS1000008I1 (hu)	2019-06-28
EP1935427A3 (de)	2011-05-25
EP1372696B1 (de)	2008-07-23
LT5063B (lt)	2003-11-25
KR100864120B1 (ko)	2008-10-16
ATE401909T1 (de)	2008-08-15
PL212205B1 (pl)	2012-08-31
IL153593A0 (en)	2003-07-06
UY26815A1 (es)	2002-01-31
PT1935427T (pt)	2018-05-16
AR035037A1 (es)	2004-04-14
EE200300004A (et)	2004-10-15
LT2003002A (en)	2003-07-25
CA2630062C (en)	2014-10-14
KR100895552B1 (ko)	2009-04-29
JP2004517806A (ja)	2004-06-17
PL207534B1 (pl)	2010-12-31
CA2413190A1 (en)	2002-01-10
ES2667203T3 (es)	2018-05-10
TR201807700T4 (tr)	2018-06-21
AR066511A2 (es)	2009-08-26
IS6667A (is)	2003-01-02
EP3384924A1 (de)	2018-10-10
RU2287340C2 (ru)	2006-11-20
PT1372696E (pt)	2008-10-24
HRP20030071A2 (en)	2005-02-28
BG66024B1 (bg)	2010-11-30
HU226847B1 (en)	2009-12-28
MXPA02012603A (es)	2003-05-14
CZ303959B6 (cs)	2013-07-17
NO20026264D0 (no)	2002-12-27
NO20026264L (no)	2003-02-19
YU101102A (sh)	2006-01-16
KR20030017606A (ko)	2003-03-03
AU2001273174C1 (en)	2002-01-14
IS2834B (is)	2013-05-15
BG66454B1 (bg)	2014-10-31

Legal Events

Date

Code

Title

Description

2011-04-15

AA1Y

Spc filed

Free format text: PRODUCT NAME: ORENCIA - ABATACEPT; REG NO/DATE: C(2007)2236 21.05.2007

Spc suppl protection certif: C20110002

Filing date: 20110303

2011-06-15

HE1A

Change of address

2011-10-17

FG1Y

Spc granted

Free format text: PRODUCT NAME: ORENCIA - ABATACEPT; REG NO/DATE: C(2007)2236 21.05.2007 C(2010)407 CORR 20.01.2010

Spc suppl protection certif: C20110002 00041